A Phase 2 Study of Nivolumab Using a Fixed Dose of 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma

A Phase 2 Study of Nivolumab Using a Fixed Dose of 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma

Abstract. The introduction of nivolumab has changed the landscape of relapsed/refractory classical Hodgkin lymphoma (r/r cHL) treatment. Despite its clinical importance, this therapy may remain inaccessible for a significant number of patients worldwide, especially in low-income countries, due to it...

Full description

Bibliographic Details
Main Authors: Kirill V. Lepik, Liudmila V. Fedorova, Elena V. Kondakova, Yuri R. Zalyalov, Elena V. Babenko, Elena E. Lepik, Polina V. Kotselyabina, Anastasia V. Beynarovich, Marina O. Popova, Nikita P. Volkov, Lilia V. Stelmakh, Vadim V. Baykov, Ivan S. Moiseev, Natalia B. Mikhailova, Alexander D. Kulagin, Boris V. Afanasyev
Format: Article
Language:English
Published: Wiley 2020-10-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000480

Internet

http://journals.lww.com/10.1097/HS9.0000000000000480

Similar Items